ArticleBMC complementary medicine and therapies2026
Yajieshaba extract improves alcohol‑induced liver injury by regulating hepatic lipid metabolism and gut microbiota.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundYajieshaba, a commonly used Dai medicine formula, is renowned for its hepatoprotective properties. This study aimed to investigate the therapeutic effects and underlying mechanisms of Yajieshaba on alcoholic liver disease (ALD) in mice, focusing the gut-liver axis.
methodsMale C57BL/6 mice were pair-fed the Lieber-DeCarli control or ethanol-containing diet for 8 weeks, with or without Yajieshaba co-administration. Serum biomarkers were assessed using biochemical kits. Liver pathology was evaluated by hematoxylin and eosin (H&E) and Oil Red O staining. Intestinal barrier integrity was assessed by H&E staining and immunofluorescence of tight junction proteins (occludin, ZO-1). Hepatic lipid composition was analyzed by liquid chromatography-mass spectrometry (LC-MS), and gut microbiota diversity was profiled by 16 S rRNA sequencing.
resultsYajieshaba significantly attenuated ethanol-induced liver injury, steatosis, and intestinal barrier disruption. Multi-omics integration revealed that Yajieshaba mitigated ALD progression by restoring gut microbial homeostasis and regulating hepatic lipid metabolism.
conclusionThis study elucidates the therapeutic mechanism of Yajieshaba from the perspective of the gut microbiome-lipid metabolism axis, providing a novel perspective and experimental basis for further ALD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.